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In the study of the role of lymphocytes in the immune response it is becoming in- 
creasingly apparent that lymphocyte membrane-bound receptors represent the recog- 
nition link between an antigen on the outside of the lymphocyte and the genetic capac- 
ity of the bTnphocyte to respond to stimulation. The first described antigen receptor 
was surface-bound immunoglobulin that characterizes bone marrow-derived lympho- 
cytes (B cells)  1 and that is absent in any appreciable quantity from thymus-derived 
lymphocytes (T  cells)  (1-4).  This  surface-bound  immunoglobulin is  similar to  hu- 
moral antibody and presumably/unctions as an antigen receptor with a  high degree 
of specificity for individual antigens. B  cells also have receptors for both  the anti- 
body (5, 6) and complement, C3, (7, 8) contained in immune complexes. The probable 
function of these latter two receptors is less clear and it was thought that since they 
require preformed antibody in order to react with antigen, they might function only 
in detection of antigens in the secondary immune response. Recently, however, it was 
shown that a  complement receptor could bind fluid phase C3  (9) and other workers 
demonstrated that fluid phase C3 was apparently required for B cell activation in the 
primary immune response  (10).  The complement receptor may therefore play a  key 
role in the primary immune response. 
Previously we had studied complement receptors on human lymphocytes and had 
noted that there was a difference in the complement receptors detected on normal as 
compared with those on leukemic lymphocytes (11). With normal lymphocytes, EAC1- 
* This work was supported by grants from the U.S. Public Health Service (AI-109758 and 
AI-10873) and the American Heart Association  (70-749). A preliminary report by the same 
authors was published in: Fed. Proc. 1973. 32:992. 
1  Abbreviations used in this paper: B ceils, lymphocytes derived from bone marrow; CRL, 
complement  receptor lymphocytes; EA, sheep erythrocytes sensitized with 3"M rabbit anti- 
body to sheep ceils; EAC, sheep erythrocyte-antibody-complement  complexes; GVB, gelatin 
Veronal buffer with 0.15 mM CaC12 and 0.5 mM MgC12 (12); HBSS,  Hanks' balanced salt 
solution;  hu, human; mo, mouse; T cells, lymphocytes either originating in the thymus or in 
other lymphoid tissues  under  the control of  the  thymus; TRFC,  human  thymus-derived 
rosette-forming ceils (T cells). 
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3hu  (EAChu)  detected just slightly more lymphocytes possessing the  complement 
receptor than did EACmo, but with most chronic lymphatic leukemia lymphocytes, 
EACmo detected 2-20-fold more complement receptor lymphocytes than did EAC1- 
3hu. It was also noted in that study that EAC1-3hu reacted 20-fold better in immune 
adherence  2 with human erythrocytes than did EACmo. The human erythrocyte  C3 
receptor  (immune adherence receptor)  thus appeared  to  possess  activity that was 
opposite to the complement receptor activity observed with leukemic lymphocytes. 
In the present study complement receptors on normal lymphocytes, chronic 
lymphatic leukemia lymphocytes,  and  erythrocytes  were  compared.  It  was 
shown  that  normal peripheral  lymphocytes have  two  different  complement 
receptors  that  are  antigenically distinct: one is a  receptor for cell-bound C3 
(C3b) and the other, a receptor for C3b that has been cleaved by the C3b inac- 
tivator. The first of these two receptors appears to be identical with the immune 
adherence receptor found on erythrocytes. Both receptors were also found in 
lymphoblastoid cell lines. Most chronic lymphatic leukemia lymphocytes were 
found to have the receptor for cleaved C3b, but only a  few of these lympho- 
cytes  possessed  the  immune adherence receptor.  Granulocytes, on  the  other 
hand, were found to have the  C3b receptor but not the receptor for cleaved 
C3b. 
Materials and Methods 
Lymphoid Cells and Granulocytes.--Blood from normal adults and patients with a confirmed 
diagnosis of chronic lymphatic leukemia was collected in heparin. Cultured lymphoblastoid 
cells, initiated from normal buffy coat cells, were a generous gift from Dr. Noburu Kashiwagi 
and Dr. Thomas Htitteroth. 
Separation of Lymphocytes.--With  normal  peripheral  blood, dextran  sedimentation  of 
erythrocytes was followed by centrifugafion on Hypaque-Ficoll in which most of the phago- 
cytes were pelleted, due to having been previously weighted with carbonyl iron. Poly-L-lysine- 
sensitized carbonyl iron particles were purchased from Technicon Instruments Corp., Tarry- 
town, N. Y. The carbonyl iron from one bottle of Technicon Lymphocyte Separation Reagent 
was resuspended in 15 ml of 1.6% dextran T-250 (Pharmacia Fine Chemicals, Inc., Piscataway, 
N. J.) in Hanks' balanced salt solution (HBSS) containing twice the normal amounts of CaCI2 
and MgC12, 100 U/ml of penicillin, and 100/zg/ml of streptomycin  (carbonyl iron reagent). 
Heparinized blood was mixed in a ratio of 2:3 with the carbonyl iron reagent for 1 h at 37°C 
on an inversion rotator at 15 rpm. After allowing the erythrocytes to sediment at room tem- 
perature  for 20 rain, the leukocyte-rich supernate was removed and diluted with an equal 
volume of ice-cold normal saline and 20 ml was layered onto 5 ml of ice-cold Hypaque-Ficoll 
(12% Hypaque in 8% Ficoll, d  =  1.095 g/ml) in siliconized 23 X  105 mm glass centrifuge 
tubes. These were centrifuged at 4°C for 30 min at 1,000 g. A layer consisting of 91-99% lym- 
phocytes was aspirated from the interface. After two washes in ice-cold  normal saline, the cells 
were resuspended at 2 X  106/ml in RPMI-1640 (Microbiological  Associates, Inc., Bethesda, 
Md.). No evidence of selective depletion of B or T cells was obtained when the percentages of 
2 Immune adherence, first described by Nelson in 1953 (13), is the agglutination of EAC 
(or any immune complex that fixes complement) with primate  erythrocytes  by way of the 
C3b (14) on the EAC and the C3b receptor found on primate (and not on nonprimate) erythro- 
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cells with surface immunoglobulin and complement receptors and  thymus-derived rosette- 
forming cells were checked after each purification step and also after parallel purifications by 
other less efficient procedures (15, 16). With leukemic peripheral blood the carbonyl iron step 
was unnecessary because the leukocytes were usually composed of 90-99% lymphocytes. After 
sedimentation of erythrocytes with 3% dextran, the lymphocytes were isolated by Hypaque- 
Ficoll (d =  1.08 g/ml) flotation as previously described (11). 
Separation of Granuloeytes.--After sedimentation of erythrocytes with 3% dextran (11), the 
leukocyte-rich supernate was resuspended in 30% fetal bovine serum in RPMI-1640 to a cell 
concentration of 2  X  106 leukocytes/ml and processed as previously described to separate 
adherent and nonadherent cells (11). Cells not adhering to  plastic Petri dishes (lymphocytes, 
erythrocytes, and platelets) were discarded. The adherent cells (granulocytes and monocytes) 
were eluted by adding 10 ml of HBSS containing 0.04 M EDTA to each Petri dish and after a 
period of 1 h at 4°C, the eluted cells were recovered. After two washes with ice-cold RPMI-1640 
the adherent cells were examined and typically contained 92% granulocytes, 6% monocytes, 
and 2% lymphocytes. 
Erythrocyte-Antibody-Complement Complexes (EA C).--EA, EAC14°~y23hu (EAC1-3hu),  and 
EAC1423mo  (EACmo)  were prepared as previously described (11). EAC1-3huIn were pre- 
pared by treating EAC1-3hu with 8 U of purified C3b inactivator (17) for 1 h at 37°C, followed 
by two washes in ice-cold GVB. 1 U of C3b inactivator is that amount required for 50% inhibi- 
tion of immune adherence utilizing EAC 1-3hu and human erythrocyte indicator cells. When 8 
U of C3b inactivator were used, inhibition of immune adherence was usually greater than 95%. 
However, if inhibition was less than this amount, a second treatment of the complex with C3b 
inactivator was performed. 
EA(G)  were prepared by incubating EA at a  concentration of 2.5  )<  108/ml with 1% 
glutaraldehyde in saline at 37°C for 15 rain. This fixation procedure was previously shown to 
permit complement activation on the surface of the cell but to prevent hemolysis even when a 
large excess of whole complement was employed. 3 EAChu(G) were prepared by incubating 
EA(G) at 2 X  108/ml with an equal volume of whole human serum diluted 1:2.5 for 30 min 
at 37°C. After this procedure the unlysed red cells were washed twice with ice-cold GVB. 
Detection of Complement Receptor Lymphocytes (CRL) and Thymus-Derived Rosette-Forming 
Cells (TRFC).--CRL and  TRFC  were  measured as previously described except that  the 
medium used was RPMI-1640, instead of 0.04 M EDTA-HBSS =  (11). 
Immunofluoreseence.--Detection of surface immunoglobulin-bearing cells was performed as 
previously described except that the anti-immunoglobulin treatment was carried out in the 
presence of 0.03 M NaN3  (2, 11). 
Immune Adherence.--Rosettes of human erythrocytes and EAC were measured microscopi- 
cally by a procedure similar to that used for the detection of complement receptor lymphocyte 
rosettes, except that human erythrocytes were substituted for lymphocytes and an incubation 
time of 30 min was used instead of 15 min. Rosettes with 2, 3, 4 or more attached EAC were 
separately enumerated and the average number of EAC  bound per  10~) erythrocytes was 
calculated. 
rDetection of Granulocyte Rosettes.--0.4 ml of granulocytes at 2 X  106/ml was mixed with 0.4 
ml of EAC at 1 X  10S/ml in a similar manner as that used for detection of CRL or erythrocyte 
immune adherence rosettes. Incubation on the rotator was only 5 min, since longer periods of 
incubation were found to produce clumps of rosettes and phagocytosis  of the EAC. 
Antilymphocyte and Antierythrocyte Sera.--Antilymphocyte sera were prepared in rhesus 
monkeys and were the generous gift of Dr.  Arthur Malley. Monkeys were injected intra- 
muscularly with whole cell suspensions containing 1-3 X  l0 s cells in Freund's complete adju- 
vant at 2-wk intervals for a period of 3-6 mo. Spleen cells were obtained at autopsy of an adult 
with no known gross immunological defect. The leukemic lymphocytes used for immunization 
were peripheral lymphocytes  isolated from the whole blood of a patient with chronic lymphatic 
3 Policy, M. J. Unpublished observation. ROSS~ POLLEY,  RABELLINO,  AND  GREY  801 
leukemia. The brain tissue used for immunization was obtained at autopsy from the cortex 
region of a 2 mo old child. Thymus cells were from autopsy of a 3 mo old child. The cultured 
lymphoblastoid cells used for immunization were from a  culture line initiated from normal 
buffy coat cells.  Antierythrocyte serum was prepared in rabbits by immunization at 2-wk 
intervals with 2 X  10  9 human erythrocytes, first intravenously in saline, then intraperitoneally 
in saline, and finally intramuscularly in Freund's complete adjuvant. The rabbits were bled 4 
wk after the last immunization. When tested by Ouchterlony analysis, none of the antisera 
reacted with normal human serum. The antierythrocyte serum was absorbed three times with 
1/10 vol of human erythrocyte ghosts previously treated with papain in order to render them 
immune adherence negative (18). 
Assay for Inhibition of Complement Receptors by Antiserum.--0.2  ml of heat-inactivated 
(56°C 30 rain) antiserum diluted in 0.03 M  NaN3-HBSS was added to a pellet of 6 X  106 cells 
and allowed to stand at 0°C for 45 rain, during which time the suspension was mixed with a 
Pasteur pipet every 15 min. The mixture was centrifuged, the supernate was discarded, and 
the cells,  after 3 washes in ice-cold 0.03 M  NaN3-HBSS, were resuspended in 2 ml of ice-cold 
RPMI-1640 and tested for either CRL  or immune adherence. Controls included untreated 
cells and cells treated with heat-inactivated normal rhesus monkey or rabbit serum. 
Assay of Antilymphocyte Sera for Cytotoxlcity and Immunofluorescence.--The amount of 
antibody directed to lymphocytes in the various sera was quantitated by SlCr release using 
rabbit complement and normal or leukemic lymphocyte target cells as previously described 
(19). The anfilymphocyte sera were also studied by indirect immunofluorescence using a rabbit 
anti-rhesus monkey "y-globulin conjugated with fluorescein isothiocyanate (2). This antiserum 
was prepared in rabbits previously made tolerant to human 7-globulin (20). 
Fob Fragments of Antimouse C3.--Rabbit antiserum to mouse C3 was prepared  (21)  and 
monovalent papain fragments of the "y-globulin fraction of the serum were isolated (22). 
RESULTS 
CRA,  Surface  Immunoglobulin,  and  TRFC  in  Cultured  Lymphoblastoid 
CeUs.--Lymphoblastoid  cell  lines were  initiated from  normal  buffy  coat  cells 
either with no addition of virus or with the addition of a  freeze-thaw lysate of 
a  previously established culture (23). Each of the cell lines tested resembled B 
cells,  since  all  had  surface  immunoglobulin,  CRL,  and  totally  lacked  TRFC 
(Table  I).  As in  tests  with  normal  lymphocytes,  EAC1-3hu  usually  detected 
TABLE  I 
CRL,  Surface Immunoglobulin (SIg),  and  Thymus-Derived Rosette-Formlng Cells (TRFC) 
in Cultured Lymphoblastoid Call Lines 
CRL  + 
Cell line  SIs  '+  TRFC  + 
EACmo  EAC1-3hu 
%  %  %  % 
Be.-C  75  82  51  0 
Mo.-A  64  76  30  0 
Ib.-h  88  89  31  0 
Iw.-B  32  42  25  0 
P.G.-L.C.  73  38  54  0 
H.H.  84  97  24  0 
T.M.  93  74  63  0 
M.W.  93  70  46  0 802  TWO  DIFFERENT  COMPLEMENT  RECEPTORS 
slightly more CRL than did EACmo (11). However, in three out of eight cul- 
tures  tested  (P.G.-L.C.,  T.M.,  and  M.W.),  the  cells  resembled  leukemic 
lymphocytes in that more cells with a complement receptor were detected with 
EACmo  than with EAC1-3hu.  In  addition,  the  rosettes formed were clearly 
stronger in  that  more EAC  were bound per rosette with EACmo  than  with 
EAC1-3hu. 
Evidence for Two Antigenically Distinct Complement Receplors.--In order to 
study further the differences in the reactivity of EACmo and EAC1-3hu with 
different cells,  antisera prepared to various whole cells  were employed. Since 
spleen cells  (11)  and most cultured cell lines (in particular Ib.-A of Table I) 
contained  large  numbers  of cells  reacting  nearly equally with  EACmo  and 
EAC1-3hu,  these cells  were used as immunogens in order to produce an anti- 
body to "normal" complement receptor lymphocytes. Leukemic lymphocytes 
from  a  patient  (J.M.  of Table IV)  whose  cells were  strongly reactive with 
EACmo (62 %) but almost completelyunreactive with EAC1-3hu (1%) were se- 
lected to produce an antiserum directed to tile reactivity observed with EACmo. 
Since human  erythrocytes formed strong  rosettes with  EAC1-3hu  but  were 
usually unreactive or poorly reactive with EACmo, rabbits  were immunized 
with human erythrocytes to produce an antiserum with reactivity to the im- 
mune adherence receptor. As a  specificity control, rhesus monkeys were also 
immunized with thymus and brain tissue, since T cells and brain tissue, though 
probably sharing  many antigens  with  B  cells,  were not  believed  to  possess 
complement receptors. 
The rhesus monkeys were hyperimmunized over a period of 3-6 mo and  all 
of  the  antisera  produced  were  shown  by  indirect  immunofluorescence  and 
cytotoxicity to contain antibodies of high titer directed to antigens shared  by 
both B  and T  cells.  When the antisera were tested for their ability to  inhibit 
complement receptors, only the antisera produced with immunogens containing 
B  cells  had  such activity. No inhibition was  obtained with  the  antithymus, 
antibrain,  or  normal  (rhesus  monkey or  rabbit)  sera.  Complement  receptor 
inhibition activity was found only in late bleedings from animals that at  this 
time had also developed a high cytotoxic titer. With the rabbit antierythrocyte 
sera, no complement receptor inhibition activity was detectable when the  sera 
were used in subagglutinating doses. However, when 90 % of the agglutinating 
antibody in these sera was  absorbed with papain-treated,  immune adherence 
negative erythrocytes, one out of three antierythrocyte sera inhibited immune 
adherence with untreated erythrocytes. 
The results of the antisera inhibition  assays  (Table II)  indicated  that  the 
complement receptors for EACmo and EAC1-3hu were antigenically distinct. 
Whereas the antibodies  to spleen and lymphoblastoid cells inhibited rosettes 
with  both  EACmo  and  EAC-3hu,  antibody  to  leukemic  lymphocytes only 
inhibited  rosettes formed with EACmo  and no inhibition was  detected with 
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serum only inhibited rosettes with EAC1-3hu. However,  with normal lympho- 
cytes and with erythrocyte target cells it inhibited rosettes with both EAC1-3hu 
and EACmo. This apparent dual specificity was explained later when the speci- 
ficity of the two receptors was demonstrated. When the antisera  to spleen and 
to cultured cells  were  absorbed with erythrocytes, the  ability of the antisera 
to inhibit  EAC1-3hu rosettes  was  completely removed;  however,  this  proce- 
dure had little or no effect on the ability of these sera to inhibit EACmo rosettes 
with lymphoblastoid or leukemic target cells. 
TABLE II 
Inhibition of Complement Receptors by Antisera Directed to Various Cells 
Antiserum  Target cell 
Inhibition of rosette formation 
EACmo  EAC1-3hu 
Antispleen 
%  % 
NPL*  87  78 
CLL  96  88 
CLB  90  87 
E  94  85 
Anti-CLB  NPL  20  35 
CLL  66  57 
CLB  100  99 
E  100  94 
Anti-CLL  NPL  41  0 
CLL  96  0 
CLB  52  0 
Anti-E  NPL  55  88 
CLL  0  46 
CLB  0  75 
E  80  70 
* NPL, normal peripheral lymphocytes; CLL, chronic lymphatic leukemia lymphocytes; 
CLB, cultured lymphoblastoid  cells; E, human erythrocytes. 
A  Receptor for C3b Inactivator-Cleaved C3b.--Since the EACmo was prepared 
with C5-deficient mouse serum, the complex probably contained two different 
forms of C3,  C3b and products of C3b cleavage (C3c and C3d) produced by 
the  C3b  inactivator  contained  in  the  serum.  On  the  other  hand,  since  the 
EAC1-3hu was  prepared  with  purified  components,  it  contained  only  C3b. 
The observation that immune adherence with human erythrocytes and EACmo 
was poor compared with that with EAC1-3hu was further suggestive evidence 
of this postulate. Since Fab fragments of antimouse C3 completely blocked the 
reaction between EACmo and leukemic lymphocytes, one of the forms of C3 
was  clearly  responsible  for  this  activity.  To  determine  whether  the  greater 804  TWO  DIFFERENT  COMPLEMENT  RECEPTORS 
activity of EACmo over EAC1-3hu with most leukemic and with some lympho- 
blastoid  cell  lines  was  due  to  a  receptor  for  C3b  inactivator-cleaved  C3b, 
EAC1-3huIn was produced by treating EAC1-3hu with sufficient  C3b  inacti- 
vator to cleave more than  95%  of the  C3b  to C3c and  C3d as measured by 
inhibition  of immune adherence.  EAC was  also prepared  with  whole human 
serum in an  analogous manner to that used  to produce EACmo, except that 
the EA were fixed with glutaraldehyde in order to prevent lysis subsequent to 
the  addition  of  whole  complement EAChu(G).  The  results  of  these  experi- 
ments (Table III) indicated that the rosette-forming activity of EAC1-3hu was 
much  increased  with  both  leukemic  lymphocytes and  lymphoblastoid  cells 
after  treatment  of  the  red  cell  complement  complex  with  C3b  inactivator. 
TABLE III 
CRL  in  Normal  Peripheral  Blood (NPB),  Chronic Lymphatic  Leukemia  Peripheral Blood 
(CLL),  and Cultured Lymphoblastold Cells (CLB) 
CRL  + 
EACmo  EACI-3hu  EACl-3huIn  EAChu(G) 
NPB 
CLL 
CLB 
%  %  %  % 
8  10  5  7 
D.H.  79  39  77  67 
F.H.  46  3  44  38 
R.H.  59  6  54  59 
T.M.  98  77  95  96 
M.W.  90  40  88  92 
Since this activity was found to closely resemble the activity seen with EACmo, 
it was  concluded that  the  receptor for EACmo demonstrated with  the  anti- 
serum to leukemic cells was a receptor for C3b inactivator-cleaved C3b.  Titra- 
tion of purified  C3 by microscopic immune adherence  demonstrated  that the 
residual 5 % of immune adherence remaining subsequent to treatment of EAC1- 
3hu with C3b inactivator could be accounted for by as few as 100 molecules of 
C3b per EAC1-3huIn: an amount previously shown to be incapable of detect- 
ing  complement receptor  cells  with  normal  peripheral  or  chronic  lymphatic 
leukemia lymphocytes (11). On the other hand, immune adherence with EACmo 
and EAChu(G) was 10-70% of that obtained with EAC1-3hu, so it is probable 
that the EAC prepared with the whole serum either of human or mouse origin 
contained significant amounts of C3b as well as C3b that had been cleaved by 
C3b  inactivator.  Thus it appeared  that EACmo reacted  with  both  types  of 
complement receptors,  and  when both  types of receptors were  present  on  a ROSS,  POLLEY,  RABELLINO,  AND  GREY  805 
single type of target cell,  antisera inhibition of only one of the two types of 
receptors would still allow EACmo to form rosettes dependent on the other 
type of receptor. This was also apparently the explanation for the antierythro- 
cyte  serum  causing  55%  inhibition  of  rosettes  between  normal  peripheral 
lymphocytes and EACmo (Table II). As shown in Table III, normal peripheral 
lymphocytes contained 10%  of cells with the C3b  receptor (10%  CRL with 
EAC1-3hu) and 5 % of cells with the receptor for cleaved C3b (5 % CRL with 
EAC1-3huIn).  Since 8%  CRL were detected with  EACmo, it was probable 
that this complement complex was detecting both C3 receptors and that only 
the  C3b  receptor  was  inhibited  by  the  antibody to  erythrocytes. Further, 
since  human  erythrocytes only  contained  the  immune  adherence  receptor, 
EACmo reacted with erythrocytes only through the C3b contained in the com- 
plex,  and therefore the antierythrocyte serum,  which inhibited only the im- 
mune adherence receptor, would strongly inhibit immune adherence rosettes 
with EACmo when erythrocyte target cells were employed (Table II). EAC1- 
3hu,  on  the  other  hand,  contained little  if  any cleaved  C3b  and  therefore 
reacted only with cells having the uncleared C3b receptor (immune adherence 
receptor).  For this  reason,  the anti-chronic  lymphatic leukemia lymphocyte 
serum,  which  only inhibited  the  receptor  for  cleaved  C3b,  did  not  inhibit 
EAC1-3hu  rosettes  while it  completely inhibited rosettes with EAC1-3huIn 
(data not shown). 
Complement Receptors in  Chronic Lymphatic  Leukemia.--In  most  cases  of 
chronic lymphatic leukemia tested in this study, the lymphocyte immune ad- 
herence receptor was partially or completely missing, while the  receptor for 
cleaved C3b was retained. Table IV shows the results of testing 19 patients 
with chronic lymphatic leukemia. 15 of 18 patients' lymphocytes tested reacted 
2-60-fold better with EACmo than with EAC1-3hu. Lymphocytes from one 
patient  (S.V.)  gave more  rosettes  with  EAC1-3hu  than with EACmo.  The 
same lymphocytes also formed less rosettes with EAC1-3huIn (71% CRL) and 
EAChu(G)  (72%  CRL)  than with EAC1-3hu,  a  finding that indicated  the 
presence  of a  large number of cells  with receptors  for  C3b.  When tests for 
immune adherence receptors were performed on erythrocytes from three of the 
patients whose lymphocytes reacted very poorly with EAC1-3hu, it was found 
that their erythrocytes gave a percentage of immune adherence rosettes in the 
high normal range. 
Complement Receptors on Granulocytes.--Since  previous investigators (24, 25) 
have demonstrated C3  receptors on granulocytes, it was of interest to deter- 
mine whether granulocytes had receptors for both C3b and C3b inactivator- 
cleaved  C3b.  In  the present study, more than 90%  of granulocytes formed 
strong rosettes with EAC1-3hu, but fewer rosettes were formed with EACmo. 
Rosette formation was maximum within 3-5  min after the EAC were added 
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phagocytized as many as five complement-coated cells. As has been shown with 
lymphocytes, neither EA  (prepared with  ~,M  antibody)  nor  the  EAC14°xr2 
used to form the EAC1-3hu formed rosettes with granulocytes. 
In  contrast  to  the  results  obtained  with  lymphocytes, EAC1-3hu  treated 
with  C3b inactivator in an amount shown to inactivate 98 %  of the immune 
adherence activity no longer formed rosettes with granulocytes. Thus it was 
concluded that granulocytes have receptors for C3b but probably do not have 
receptors for C3b inactivator-cleaved C3b. 
TABLE  IV 
CRL,  Surface  Immunoglobulin  (SIg),  and  Thymus-Derived  Rosette-Forming Cells (TRFC) 
in Chronic Lymphatic Leukemia 
CRL  + 
Patient  SIg  +  TRFC  + 
EACmo  EACI-3hu 
%  %  %  % 
J.AI.  41  23  80  n.d.* 
.[.An.  70  18  100  n.d. 
H.C.  15  n.d.  60  n.d. 
A.H.  55  11  13  1 
D.H.  79  39  74  18 
F.H.  46  3  73  27 
R.H.  59  6  47  32 
T.H.  10  1  <I  3 
J.M.  62  1  70  3 
A.O.  84  73  26  n.d. 
E.S.  61  7  5  n.d. 
L.S.  10  9  68  n.d. 
V.S.  13  3  4  1 
W.S.  31  1  <i  <I 
R.T.  62  3  12  3 
W.T.  47  9  24  n.d. 
R.V.  65  33  1  n.d. 
S.V.  72  79  62  21 
B.Z.  59  39  n.d.  7 
* n.d., not done. 
DISCUSSION 
In previous studies  (11,  26)  our data  suggested  that  human  lymphocytes 
possessed two complement receptors, one for human C3 and one for mouse C3. 
Further, that in most cases, only the receptor for mouse C3 was detectable on 
chronic  lymphatic  leukemia  cells.  This  finding  concerning  the  receptor  on 
leukemic  cells  seemed  to  explain  the  apparently  contradictory  findings  of 
several previous investigators who had prepared their EAC with either whole 
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our own  studies  (11,  26)  we had  similarly used  whole mouse  serum for the 
detection of the mouse C3 receptor and purified components of human comple- 
ment for the detection of the human C3 receptor. Thus, in addition to a species 
difference between the sources of complement employed, there was also a dif- 
ference between the C3 fixed when complement was supplied by whole serum 
as compared with that fixed when purified complement components were used. 
The  whole  mouse  serum  contained  C3b  inactivator that  would  cleave  cell- 
bound  C3b  into  two fragments,  C3c  and  C3d,  in  such  a  way that  the  C3c 
fragment was liberated from the cell while only the  C3d fragment remained 
cell  bound  (30).  When  highly  purified  components  of  human  complement 
were used instead of whole mouse serum, no C3b inactivator was present, and 
the C3 on the complex was in the form C3b. In experiments designed to dis- 
tinguish  between these two possibilities for the explanation of the difference 
in reactivity between EAC1-3mo and EAC1-3hu, it was found that the pres- 
ence of the C3b inactivator during the preparation of EAC1-3mo was indeed 
responsible. The two complement receptors were distinguishable,  not by the 
difference in species, mouse or human, but by the cell-bound C3 in the EAC1-3 
complex being either in the form C3b or C3b inactivator cleaved C3b(C3d). 
The two receptors can only be measured individually if the EAC  contain 
only one form of C3.  In experiments in which whole serum was used as the 
source  of  complement,  it  was  not  consistently possible  to  prepare  EACmo 
[or EAChu(G)]  that  was  completely immune  adherence negative,  that  is  to 
say, in which all the cell-bound C3 had been cleaved by the C3b inactivator. 
However,  utilizing  purified  components,  the  two  receptors  could  be  easily 
distinguished,  since EAC1-3  could be prepared in which the C3 was  entirely 
in the form C3b,  and then this  complex could be reacted with purified C3b 
inactivator to produce a second type of indicator complex, EAC1-3In, in which 
most of the cell-bound C3b had been cleaved into C3c and C3d. Since Ruddy 
and Austen (30) have demonstrated that C3b inactivator treatment of EAC1- 
3hu causes release into the fluid phase of most of the C3c but little of the C3d, 
it is most likely that  the receptor for inactivator-cleaved C3b  is specific for 
the C3d fragment of C3. 
In order to further distinguish between the two receptors, experiments were 
performed  utilizing  antisera  produced  against  various  types  of  cells.  Since 
these  antisera  were  produced  against  whole  cells,  none  was  specific for the 
complement receptors. However, they were found to be capable of distinguish- 
ing between the two complement receptors, Utilizing the antiserum produced 
against  chronic lymphatic leukemia lymphocytes, it was  found that  the im- 
mune adherence (C3b) receptor was antigenically missing or reduced from the 
lymphocytes of these individuals. However, the complement receptor on these 
leukemic cells was antigenically related to a receptor found on normal B  cells, 
since it was inhibited by the antispleen serum and since the antileukemic cell 
serum inhibited the cleaved C3b (C3d) receptor of normal lymphocytes. Thus 808  TWO  DIFFERENT  COMPLEMENT  RECEPTORS 
it became apparent that with most chronic lymphatic leukemic lymphocytes, 
the only complement receptor that was readily detectable was that for cleaved 
C3b  (C3d)  and the C3b receptor was either absent or present in a  much re- 
duced amount. Both receptors were found to be present on normal peripheral 
lymphocytes  and  on  cultured  lymphoblastoid  cells,  but  only  the  immune 
adherence (C3b)  receptor, and not  the  C3d receptor, was found on erythro- 
cytes. 
In previous studies  (31)  a  biologic activity has been attributed to the C3d 
fragment of C3  that is neither present in the native C3 molecule nor  in  C3b 
i.e., that it is agglutinable  by conglutinin. It was found that conglutinin ag- 
glutinates immune  complexes containing  C3  (such  as EAC1-3hu)  only after 
treatment  of the  complex with  conglutinogen-activating factor (KAF)  (32). 
This factor was later shown to be identical to the C3b inactivator (33). The 
conglutination reaction, like the receptor for cleaved C3b on lymphocytes, is 
specific for C3b only subsequent  to its cleavage by C3b inactivator.  Studies 
are now under way to determine whether conglutinin is related to the lympho- 
cyte receptor for C3d. 
The finding of a receptor for C3b inactivator cleaved C3b (C3d) is of interest, 
since it means that it is possible for circulating immune complexes to become 
bound to lymphocytes despite the presence of C3b inactivator in serum. The 
observation  that  only the  receptor for  C3b  (immune  adherence receptor)  is 
present  on erythrocytes suggests  that  in  an in vivo situation,  if an  immune 
complex became bound  to an  erythrocyte by the  C3b  receptor, it  might be 
released by cleavage of the  C3b  by the  C3b  inactivator and then could con- 
ceivably become bound  to a  lymphocyte. The lack of a  receptor for cleaved 
C3b  on granulocytes is  possibly balanced  by their possessing  a  receptor  for 
IgG (24) and one for C44 that is considerably more effective in binding immune 
complexes than that found on !ymphocytes. 
SUMMARY 
In the present study it was shown that normal peripheral lymphocytes have 
two different complement receptors: one for C3b  (the immune adherence re- 
ceptor) and one for C3b subsequent to its cleavage by C3b inactivator. The two 
receptors are not cross-reactive and were shown by tests with various antisera 
to be antigenically distinct. Both the immune adherence receptor and the re- 
ceptor  for  C3b  inactivator-cleaved  C3b  were  found  on  normal  peripheral 
lymphocytes and  on  cultured  lymphoblastoid  cells.  In  15  out  of  18  chronic 
lymphatic  leukemia  patients,  the  immune  adherence  receptor  was  either 
partially or  completely missing  from  the  peripheral  lymphocytes, while  the 
lymphocyte receptor for C3b  inactivator-cleaved C3b  was  retained.  Normal 
erythrocytes, on the other hand, were found to have only the immune adherence 
4 Ross, G. D., and M. J. Polley, manuscript in preparation, ROSS, POLLEY~ RABELLINO, AND  GREY  809 
receptor. Granulocytes from normal peripheral blood appeared to have only a 
receptor for C3b and did not have a  receptor for C3b inactivator-cleaved C3b. 
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